US20050234104A1 - 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as medicament - Google Patents
3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as medicament Download PDFInfo
- Publication number
- US20050234104A1 US20050234104A1 US10/918,017 US91801704A US2005234104A1 US 20050234104 A1 US20050234104 A1 US 20050234104A1 US 91801704 A US91801704 A US 91801704A US 2005234104 A1 US2005234104 A1 US 2005234104A1
- Authority
- US
- United States
- Prior art keywords
- methyl
- ylamino
- pyridin
- carbonyl
- phenylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- KSGXQBZTULBEEQ-UHFFFAOYSA-N CCCCCCOC(=O)/N=C(/N)C1=CC=C(NCC2=NC3=C(C=CC(C(=O)N(CCC(=O)OCC)C4=NC=CC=C4)=C3)N2C)C=C1.CS(=O)(=O)O Chemical compound CCCCCCOC(=O)/N=C(/N)C1=CC=C(NCC2=NC3=C(C=CC(C(=O)N(CCC(=O)OCC)C4=NC=CC=C4)=C3)N2C)C=C1.CS(=O)(=O)O KSGXQBZTULBEEQ-UHFFFAOYSA-N 0.000 description 1
- YBSJFWOBGCMAKL-UHFFFAOYSA-N CN1C2=CC=C(C(=O)N(CCC(=O)O)C3=NC=CC=C3)C=C2N=C1CNC1=CC=C(C(=N)N)C=C1 Chemical compound CN1C2=CC=C(C(=O)N(CCC(=O)O)C3=NC=CC=C3)C=C2N=C1CNC1=CC=C(C(=N)N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to the compound ethyl 3-[(2- ⁇ [4-(hexyloxycarbonylaminoimino-methyl)phenylamino]methyl ⁇ -1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate of formula A and the use thereof as a pharmaceutical composition.
- the base of the compound of formula A is already known from WO 98/37075, in which compounds with a thrombin-inhibiting effect and a thrombin time-prolonging activity are disclosed, under the name 1-methyl-2-[N-[4-(N-n-hexyloxycarbonylamidino)phenyl]-aminomethyl]benzimidazol-5-ylcarboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-amide.
- the compound of formula I is a double prodrug of the compound of formula B i.e., the compound of formula A (BIBR 1048 MS) is only converted into the actual effective compound, namely the compound of formula B, in the body.
- the main fields of application of the compound of chemical formula A are the post-operative prophylaxis of deep vein thrombosis and the prevention of stroke.
- examples of these parameters are the stability of effect of the starting substance under different ambient conditions, stability in the course of the preparation of the pharmaceutical formulation, and stability in the final compositions of the pharmaceutical preparation.
- the pharmaceutical active substance used to prepare the pharmaceutical compositions should therefore have high stability, which should also be guaranteed even under different environmental conditions. This is absolutely essential to prevent the use of pharmaceutical compositions which contain, in addition to the active substance itself, breakdown products thereof, for example. In such cases the content of active substance found in the pharmaceutical formulations might be less than specified.
- the absorption of moisture reduces the content of pharmaceutically active substance as a result of the increased weight caused by the uptake of water.
- Pharmaceutical compositions with a tendency to absorb moisture have to be protected from moisture during storage, e.g., by the addition of suitable drying agents or by storing the drug in an environment where it is protected from moisture.
- the uptake of moisture may reduce the content of pharmaceutically active substance during manufacture if the pharmaceutical substance is exposed to the environment without being protected from moisture in any way.
- a pharmaceutically active substance should be only slightly hygroscopic.
- the problem of the present invention is to provide a pharmaceutically active substance which not only is characterized by high pharmacological potency but also satisfies the abovementioned physicochemical requirements as far as possible.
- FIG. 1 shows the X-ray powder diffractograms of the three crystalline forms of ethyl 3-[(2- ⁇ [4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl ⁇ -1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate.
- FIG. 2 shows the thermoanalysis and measurement of the melting point (DSC) for the three crystalline forms of ethyl 3-[(2- ⁇ [4-(hexyloxycarbonylaminoiminomethyl)phenylamino]-methyl ⁇ -1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate.
- a hydrate form may be obtained, the water content of which indicates a hemihydrate.
- the active substance contained therein is in a uniform crystalline modification to ensure reliable bioavailability.
- the methanesulfonate according to the invention is characterized in all three crystalline modifications by good crystallinity and low amorphization during grinding and compression. Moreover, it is non-hygroscopic in all three crystalline modifications and dissolves very easily in physiologically acceptable acid aqueous media.
- Polymorphic forms of the salt ethyl 3-[(2- ⁇ [4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl ⁇ -1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate preferably in
- the invention also relates to the methods of selectively producing the three polymorphic forms as well as the modifications which may be obtained by these methods.
- BIBR 1048 MS polymorph I is obtained by:
- BIBR 1048 MS polymorph II is obtained by:
- BIBR 1048 MS hemihydrate is obtained by:
- the hydrate of the compound ethyl 3-[(2- ⁇ [4-(hexyloxycarbonylaminoiminomethyl)phenyl -amino]methyl ⁇ -1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate according to the invention occurs in the form of the hemihydrate under standard conditions, from which water escapes at a temperature of about 120° C., parallel to the melting of this form.
- FIG. 2 shows the thermoanalysis of the three forms.
- This synthesis may also be carried out by inoculating with BIBR 1048 MS polymorph II. If the speed of conversion is low, it may be accelerated by the addition of a small amount of BIBR 1048 base (for example, on an industrial scale, about 50 g of BIBR 1048 base to roughly 90 kg of BIBR 1048 MS polymorph I) in addition to the inoculation with BIBR 1048 MS polymorph II.
- a small amount of BIBR 1048 base for example, on an industrial scale, about 50 g of BIBR 1048 base to roughly 90 kg of BIBR 1048 MS polymorph I
- This synthesis may also be carried out without inoculation with BIBR 1048 MS polymorph II. However, the method using inoculation is preferred.
- BIBR 1048 MS polymorph I 30.7 kg of BIBR 1048 MS polymorph I is placed in an agitator apparatus which has been rendered inert and then 199 kg of acetone is added.
- the contents of the apparatus are inoculated with 10 g of BIBR 1048 MS polymorph II (e.g., prepared according to Example 2), heated to 40° C. to 46° C. with stirring, and kept at this temperature for at least 1 hour. Then the mixture is cooled to 17° C. to 23° C. and stirred for at least a further 40 to 80 minutes.
- the crystal suspension is separated off using a horizontal centrifuge and washed with a total of 45 kg of acetone.
- the product is dried in a vacuum drying cupboard at a maximum temperature of 50° C. for at least 4 hours. Yield: 27.7-30.1 kg; 90%-98% of theory).
- This synthesis may also be carried out without inoculation with BIBR 1048 MS polymorph II. However, the method using inoculation is preferred. If the speed of conversion is low, a small amount of BIBR 1048 base (for example, about 50 g of BIBR 1048 base to roughly 90 kg of BIBR 1048 MS polymorph I) may be added, in addition to the inoculation with BIBR 1048 MS polymorph II.
- the product began to crystallize out and was diluted with 30 mL of ethyl acetate. It was stirred for another 30 minutes at 35° C. to 40° C. and for a further 30 minutes at ambient (room) temperature, then the precipitate was suction filtered, washed with approximately 20 mL of ethyl acetate, and dried at 40° C. in the circulating air drying cupboard.
Abstract
Ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate in the crystalline modifications I and II and as the hemihydrate and the use thereof as a pharmaceutical composition.
Description
- This application claims benefit of U.S. Ser. No. 60/503,316, filed Sep. 16, 2003, and claims priority to German Application No. DE 103 39 862.7, filed Aug. 29, 2003, each of which is hereby incorporated by reference in its entirety.
-
- The base of the compound of formula A is already known from WO 98/37075, in which compounds with a thrombin-inhibiting effect and a thrombin time-prolonging activity are disclosed, under the name 1-methyl-2-[N-[4-(N-n-hexyloxycarbonylamidino)phenyl]-aminomethyl]benzimidazol-5-ylcarboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-amide. The compound of formula I is a double prodrug of the compound of formula B
i.e., the compound of formula A (BIBR 1048 MS) is only converted into the actual effective compound, namely the compound of formula B, in the body. The main fields of application of the compound of chemical formula A are the post-operative prophylaxis of deep vein thrombosis and the prevention of stroke. - The abovementioned pharmacologically beneficial properties of the disubstituted bicyclic heterocycles disclosed in the prior art are the main prerequisite for effective use of the compounds as pharmaceutical compositions. An active substance must, however, also meet other requirements in order to be capable of being used as pharmaceutical compositions. These parameters are to a large extent connected with the physicochemical nature of the active substance.
- Without being restricted thereto, examples of these parameters are the stability of effect of the starting substance under different ambient conditions, stability in the course of the preparation of the pharmaceutical formulation, and stability in the final compositions of the pharmaceutical preparation. The pharmaceutical active substance used to prepare the pharmaceutical compositions should therefore have high stability, which should also be guaranteed even under different environmental conditions. This is absolutely essential to prevent the use of pharmaceutical compositions which contain, in addition to the active substance itself, breakdown products thereof, for example. In such cases the content of active substance found in the pharmaceutical formulations might be less than specified.
- The absorption of moisture reduces the content of pharmaceutically active substance as a result of the increased weight caused by the uptake of water. Pharmaceutical compositions with a tendency to absorb moisture have to be protected from moisture during storage, e.g., by the addition of suitable drying agents or by storing the drug in an environment where it is protected from moisture. In addition, the uptake of moisture may reduce the content of pharmaceutically active substance during manufacture if the pharmaceutical substance is exposed to the environment without being protected from moisture in any way. Preferably, therefore, a pharmaceutically active substance should be only slightly hygroscopic.
- As the crystal modification of an active substance is important to the reproducible active substance content of a preparation, there is a need to clarify as far as possible any existing polymorphism of an active substance present in crystalline form. If there are different polymorphic modifications of an active substance, care must be taken to ensure that the crystalline modification of the substance does not change in the pharmaceutical preparation later produced from it. Otherwise, this could have a harmful effect on the reproducible potency of the drug. Against this background, active substances characterized by only slight polymorphism are preferred.
- Another criterion which may be of exceptional importance under certain circumstances, depending on the choice of formulation or the choice of manufacturing process, is the solubility of the active substance. If, for example, pharmaceutical solutions are prepared (e.g., for infusions), it is essential that the active substance should be sufficiently soluble in physiologically acceptable solvents. It is also very important for drugs which are to be taken orally that the active substance should be sufficiently soluble.
- The problem of the present invention is to provide a pharmaceutically active substance which not only is characterized by high pharmacological potency but also satisfies the abovementioned physicochemical requirements as far as possible.
-
FIG. 1 shows the X-ray powder diffractograms of the three crystalline forms of ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate. -
FIG. 2 shows the thermoanalysis and measurement of the melting point (DSC) for the three crystalline forms of ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate. - The problem outlined above is solved by the ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate salt of formula A.
- In fact, it has been found, surprisingly, that crystalline modification I of this salt can be prepared by the process described in Example 1 and crystalline modification II of this salt can be prepared by the processes described in Examples 2 to 4, selectively and uniformly in each case.
- Moreover, under certain conditions of synthesis as described, for example, in Example 5, a hydrate form may be obtained, the water content of which indicates a hemihydrate.
- For use of the pharmaceutical composition, it is essential that the active substance contained therein is in a uniform crystalline modification to ensure reliable bioavailability.
- The methanesulfonate according to the invention is characterized in all three crystalline modifications by good crystallinity and low amorphization during grinding and compression. Moreover, it is non-hygroscopic in all three crystalline modifications and dissolves very easily in physiologically acceptable acid aqueous media.
- The crystalline forms of the methanesulfonate of the compound ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate according to the invention are characterized by a melting point of Tmp=180° C.±3° C. (form I), Tmp=190° C.±3° C. (form II), or Tmp=120° C.±5° C. (hemihydrate) (determined by DSC=Differential Scanning Calorimetry; evaluation by peak maximum; heating rate: 10° C./min). The values shown were determined using a DSC 821 e made by Messrs. Mettler Toledo.
- In a first aspect, the present invention therefore relates to the three above mentioned polymorphic forms of the salt ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate, preferably in crystalline form, characterized by melting points of Tmp=180° C.±3° C., Tmp=190° C.±3° C. or Tmp=120° C.±5° C. (determined by DSC; evaluation by peak maximum; heating rate: 10° C./min). Polymorph
- I with a melting point of Tmp=180° C.±3° C. is preferred.
- The invention also relates to the methods of selectively producing the three polymorphic forms as well as the modifications which may be obtained by these methods. According to the invention, BIBR 1048 MS polymorph I is obtained by:
-
- (a) slowly adding a solution of a slight deficiency (for example, 0.98 equivalents) of methanesulfonic acid in acetone to a solution of BIBR 1048 base in acetone at a temperature of approximately 30° C. to 36° C.;
- (b) stirring the mixture for about 1 hour at a temperature of approximately 26° C. to 33° C.;
- (c) cooling the mixture to approximately 17° C. to 23° C. and stirring for a further 40 to 80 minutes at this temperature;
- (d) suction filtering the precipitated crystals of BIBR 1048 MS form I; and
- (e) drying the product thus obtained in vacuo for at least 4 hours at a maximum temperature of 50° C.
- According to the invention, BIBR 1048 MS polymorph II is obtained by:
-
- (a) slowly adding a solution of a slight deficiency (for example, 0.98 equivalents) of methanesulfonic acid in acetone to a solution of BIBR 1048 base in acetone at a temperature of approximately 40° C. to 46° C.;
- (b) optionally inoculating the mixture with BIBR 1048 polymorph II crystals;
- (c) stirring the mixture for about 1 hour at a temperature of approximately 40° C. to 46° C.;
- (d) cooling the mixture to approximately 17° C. to 23° C. and stirring for a further 40 to 80 minutes at this temperature;
- (e) suction filtering the precipitated crystals of BIBR 1048 MS form II; and
- (f) drying the product thus obtained in vacuo for at least 4 hours at a maximum temperature of 50° C.; or by
- (a) heating a suspension of BIBR 1048 MS polymorph I in acetone to 45° C. to 50° C. for approximately 4 hours with stirring;
- (b) optionally (i) inoculating the mixture with BIBR 1048 polymorph II crystals, or (ii) inoculating the mixture with BIBR 1048 polymorph II crystals and additionally adding a small amount of BIBR 1048 base;
- (c) cooling the mixture to approximately 15° C.;
- (d) suction filtering the precipitated crystals of BIBR 1048 MS form II; and
- (e) drying the product thus obtained in vacuo for at least 4 hours at a maximum temperature of 50° C.; or by
- (a) placing
BIBR 1048 MS polymorph I in acetone; - (b) optionally (i) inoculating the mixture with a small amount of
BIBR 1048 polymorph II, or (ii) inoculating the mixture withBIBR 1048 polymorph II crystals and additionally adding a small amount ofBIBR 1048 base; - (c) heating the mixture thus obtained to 40° C. to 46° C. for at least one hour with stirring;
- (d) cooling the mixture to approximately 17° C. to 23° C. and stirring for a further 40 to 80 minutes at this temperature;
- (e) separating off the precipitated crystals of
BIBR 1048 MS form II; and - (f) drying the product thus obtained in vacuo for at least 4 hours at a maximum temperature of 50° C.
- According to the invention,
BIBR 1048 MS hemihydrate is obtained by: -
- (a) slowly adding a solution of one equivalent of methanesulfonic acid in ethyl acetate to a solution of
BIBR 1048 base in a mixture of 90% aqueous ethanol and ethyl acetate in a ratio by volume of approximately 2:5 at a temperature of approximately 35° C. to 40° C.; - (b) optionally adding more ethyl acetate as a diluent at the start of the crystallization of the product;
- (c) stirring the mixture for approximately another 30 minutes at approximately 35° C. to 40° C.;
- (d) stirring the mixture for a further 30 minutes at ambient room temperature;
- (e) suction filtering the precipitate of
BIBR 1048 MS hemihydrate; and - (f) drying the precipitate at approximately 40° C. in a circulating air drying cupboard.
- (a) slowly adding a solution of one equivalent of methanesulfonic acid in ethyl acetate to a solution of
- The crystalline forms of ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate according to the invention were investigated in more detail by X-ray powder diffraction. The diagrams obtained are shown in
FIG. 1 . Tables 1 to 3 that follow list the data obtained in this analysis.TABLE 1 X-ray powder reflections and intensities (standardized) of ethyl 3-[(2- {[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}- 1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate (form I) 2Θ [°] dhkl value [Å] intensity [%] 4.4 20.1 100 8.94 9.90 5 9.23 9.57 4 9.55 9.26 4 10.55 8.38 2 10.95 8.08 11 12.73 6.95 1 13.46 6.57 7 13.95 6.34 3 14.26 6.21 2 15.17 5.84 1 15.93 5.56 1 16.46 5.38 1 17.66 5.02 8 18.07 4.91 13 18.60 4.77 2 19.89 4.46 6 20.28 4.38 2 20.54 4.32 2 21.12 4.20 4 22.06 4.03 8 22.85 3.89 6 24.12 3.69 1 25.10 3.54 3 25.99 3.43 1 26.52 3.36 2 26.83 3.32 2 27.16 3.28 1 27.64 3.22 2 28.09 3.17 2 29.08 3.07 1 29.26 3.05 1 29.94 2.98 1 31.88 2.80 1 34.37 2.61 1 36.21 2.48 1 38.26 2.35 1 39.47 2.28 1 39.98 2.25 1 -
TABLE 2 X-ray powder reflections and intensities (standardized) of ethyl 3-[(2- {[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1- methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate (form II) 2Θ [°] dhkl value [Å] intensity [%] 4.3 20.4 100 8.72 10.1 3 9.68 9.13 1 11.15 7.93 1 12.42 7.12 2 13.59 6.51 1 13.95 6.34 1 15.11 5.86 1 15.97 5.55 1 16.52 5.36 1 17.45 5.08 1 17.86 4.96 2 18.45 4.81 1 19.22 4.61 2 19.89 4.46 2 21.46 4.14 2 21.98 4.04 1 22.48 3.95 1 23.75 3.74 1 25.29 3.52 1 28.17 3.17 1 28.59 3.12 1 -
TABLE 3 X-ray powder reflections and intensities (standardized) of ethyl 3-[(2- {[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}- 1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate (hemihydrate) 2Θ [°] dhkl value [Å] intensity [%] 3.9 22.8 100 4.4 20.1 10 5.64 15.7 2 7.57 11.8 16 8.25 10.7 17 8.77 10.1 12 9.34 9.46 7 10.69 8.27 13 11.33 7.80 3 11.66 7.58 1 11.96 7.39 1 13.04 6.78 3 14.54 6.09 11 15.16 5.84 1 16.56 5.35 13 17.27 5.13 6 17.78 4.98 12 18.75 4.73 1 19.41 4.57 3 19.95 4.45 24 20.38 4.35 4 20.84 4.26 4 21.21 4.19 12 22.22 4.00 6 22.46 3.96 5 23.05 3.85 3 23.40 3.80 4 23.85 3.73 12 24.44 3.64 7 25.30 3.52 1 25.63 3.47 1 26.22 3.40 2 26.52 3.36 3 27.06 3.29 1 27.45 3.25 2 29.27 3.05 3 30.78 2.90 2 32.32 2.77 2 32.59 2.75 2 34.31 2.61 1 34.91 2.57 1 36.04 2.49 1 37.00 2.43 1 37.84 2.38 1 38.13 2.36 1 - In the preceding Tables 1 to 3, the value “2Θ [°]” denotes the angle of diffraction in degrees and the value “dhki[Å]” denotes the specified distances in Å between the lattice planes.
- The X-ray powder diagrams were recorded, within the scope of the present invention, using a Bruker D8 Advanced diffractometer fitted with a location-sensitive detector (OED) and a Cu anode as the X-ray source (Cuα1 radiation, λ=1.5406 Å, 40 kV, 40 mA). The hydrate of the compound ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenyl -amino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate according to the invention occurs in the form of the hemihydrate under standard conditions, from which water escapes at a temperature of about 120° C., parallel to the melting of this form.
-
FIG. 2 shows the thermoanalysis of the three forms. - 52.6 kg of ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate base (which has preferably been purified beforehand by recrystallization from ethyl acetate) is placed in an agitator apparatus which has been rendered inert and then 293 kg of acetone is added. The contents of the apparatus are heated to 40° C. to 46° C. with stirring. After a clear solution has formed, the contents of the apparatus is filtered into a second agitator apparatus through a lens filter and then cooled to 30° C. to 36° C. 33 kg of acetone precooled to 0° C. to 5° C., 7.9 kg of 99.5% methanesulfonic acid, and for rinsing another 9 kg of acetone are placed in the suspended container of the second apparatus. The contents of the suspended container are added in metered amounts to the solution of ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate base at 26° C. to 36° C. within 15 to 40 minutes. Then the mixture is stirred for 40 to 60 minutes at 26° C. to 33° C. It is then cooled to 17° C. to 23° C. and stirred for a further 40 to 80 minutes. The crystal suspension is filtered through a filter dryer and washed with a total of 270 L of acetone. The product is dried in vacuo at a maximum of 50° C. for at least 4 hours. Yield: 54.5-59.4 kg; 90%-98% of theory based on ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate base.
- 4 g of
BIBR 1048MS polymorph 1 and 35 mL of acetone are placed in a glass flask with stirrer and reflux condenser. The suspension is heated to 45° C. to 50° C. with stirring and kept at this temperature for 4 hours. It is then cooled to 15° C. and the crystals are suction filtered through a Büchner funnel, washed with 20 mL of acetone, and dried in vacuo at 45° C. - This synthesis may also be carried out by inoculating with
BIBR 1048 MS polymorph II. If the speed of conversion is low, it may be accelerated by the addition of a small amount ofBIBR 1048 base (for example, on an industrial scale, about 50 g ofBIBR 1048 base to roughly 90 kg ofBIBR 1048 MS polymorph I) in addition to the inoculation withBIBR 1048 MS polymorph II. - 52.6 kg of ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate base (which has preferably been purified beforehand by recrystallization from ethyl acetate) is placed in an agitator apparatus which has been rendered inert and then 293 kg of acetone is added. The contents of the apparatus are heated to 40° C. to 46° C. with stirring. After a clear solution has formed, the contents of the apparatus are filtered into a second agitator apparatus through a lens filter. 33 kg of acetone precooled to 0° C. to 5° C., 7.9 kg of 99.5% methanesulfonic acid, and for rinsing another 9 kg of acetone are placed in the suspended container of the second apparatus. The contents of the suspended container are added in metered amounts to the solution of ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate base at 40° C. to 46° C. within 15 to 40 minutes and inoculated with 10 g of
BIBR 1048 MS polymorph II (prepared according to Examples 2, for example). Then the mixture is stirred for 40 to 60 minutes at 40° C. to 46° C. It is then cooled to 17° C. to 23° C. and stirred for a further 40 to 80 minutes. The crystal suspension is filtered through a filter dryer and washed with a total of 270 L of acetone. The product is dried in vacuo at a maximum of 50° C. for at least 4 hours. Yield: 54.5-59.4 kg; 90%-98% of theory based on ethyl 3-[(2-{[4 (hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate base - This synthesis may also be carried out without inoculation with
BIBR 1048 MS polymorph II. However, the method using inoculation is preferred. - 30.7 kg of
BIBR 1048 MS polymorph I is placed in an agitator apparatus which has been rendered inert and then 199 kg of acetone is added. The contents of the apparatus are inoculated with 10 g ofBIBR 1048 MS polymorph II (e.g., prepared according to Example 2), heated to 40° C. to 46° C. with stirring, and kept at this temperature for at least 1 hour. Then the mixture is cooled to 17° C. to 23° C. and stirred for at least a further 40 to 80 minutes. The crystal suspension is separated off using a horizontal centrifuge and washed with a total of 45 kg of acetone. The product is dried in a vacuum drying cupboard at a maximum temperature of 50° C. for at least 4 hours. Yield: 27.7-30.1 kg; 90%-98% of theory). - This synthesis may also be carried out without inoculation with
BIBR 1048 MS polymorph II. However, the method using inoculation is preferred. If the speed of conversion is low, a small amount ofBIBR 1048 base (for example, about 50 g ofBIBR 1048 base to roughly 90 kg ofBIBR 1048 MS polymorph I) may be added, in addition to the inoculation withBIBR 1048 MS polymorph II. - A solution of 1.53 g (15.93 mmol) of methanesulfonic acid in 15 mL of ethyl acetate was added dropwise to a solution of 10.0 g (15.93 mmol) of ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate base (prepared as described in WO 98/37075) in 16.5 mL of 90% aqueous ethanol and 40 mL of ethyl acetate, with stirring, at 35° C. to 40° C. After a few minutes, the product began to crystallize out and was diluted with 30 mL of ethyl acetate. It was stirred for another 30 minutes at 35° C. to 40° C. and for a further 30 minutes at ambient (room) temperature, then the precipitate was suction filtered, washed with approximately 20 mL of ethyl acetate, and dried at 40° C. in the circulating air drying cupboard.
- Yield: 99% of theory.
Claims (19)
1. The compound ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate in crystalline form, wherein the compound has a melting point of Tmp=180° C.±3° C. determined by DSC, evaluation by peak maximum, at a heating rate of 10° C./min.
2. The compound ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate in crystalline form, wherein the compound has a melting point of Tmp=190° C.±3° C. (hemihydrate), determined by DSC, evaluation by peak maximum, at a heating rate of 10° C./min.
3. The compound ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate in crystalline form, wherein the compound has a melting point of Tmp=120° C.±5° C. (hemihydrate), determined by DSC, evaluation by peak maximum, at a heating rate of 10° C./min).
4. A pharmaceutical composition comprising:
(a) ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate according to claim 1; and
(b) one or more inert carriers and/or diluents.
5. A pharmaceutical composition comprising:
(a) ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate according to claim 2; and
(b) one or more inert carriers and/or diluents.
6. A pharmaceutical composition comprising:
(a) ethyl 3-[(2-{[4-(hexyloxycarbonylaminoinminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate according to claim 3; and
(b) one or more inert carriers and/or diluents.
7. A method for the post-operative prophylaxis of deep vein thrombosis or the prevention of stroke in a patient in need thereof, the method comprising administering to the patient an effective amount of the compound of claim 1 .
8. A method for the post-operative prophylaxis of deep vein thrombosis or the prevention of stroke in a patient in need thereof, the method comprising administering to the patient an effective amount of the compound of claim 2 .
9. A method for the post-operative prophylaxis of deep vein thrombosis or the prevention of stroke in a patient in need thereof, the method comprising administering to the patient an effective amount of the compound of claim 3 .
10. A process for preparing a polymorph of ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate in crystalline form, the process comprising:
(a) slowly adding a solution of a slight deficiency of methanesulfonic acid in acetone to a solution of ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate base in acetone at a temperature of approximately 30° C. to 36° C.;
(b) stirring the mixture of step (a) for about 1 hour at a temperature of approximately 26° C. to 33° C.;
(c) cooling the mixture of step (b) to about 17° C. to 23° C. and stirring the mixture for a further 40 to 80 minutes at this temperature to precipitate crystals of ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate;
(d) suction filtering the precipitated crystals of ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate; and
(e) drying the precipitated crystals of ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate thus obtained in vacuo for at least 4 hours at a maximum of 50° C. to obtain the polymorph of ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate in crystalline form.
11. A process for preparing a polymorph of ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate in crystalline form, the process comprising:
(a) slowly adding a solution of a slight deficiency of methanesulfonic acid in acetone to a solution of ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate base in acetone at a temperature of approximately 40° C. to 46° C.;
(b) optionally inoculating the mixture of step (a) with BIBR 1048 polymorph II crystals;
(c) stirring the mixture of the previous step for about 1 hour at a temperature of approximately 40° C. to 46° C.;
(d) cooling the mixture of step (c) to approximately 17° C. to 23° C. and stirring the mixture for a further 40 to 80 minutes at this temperature to precipitate crystals of ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate;
(e) suction filtering the precipitated crystals of ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate; and
(f) drying the precipitated crystals of ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate in vacuo for at least 4 hours at a maximum of 50° C. to obtain the polymorph of ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate in crystalline form.
12. A process for preparing a polymorph of ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate in crystalline form, the process comprising:
(a) heating with stirring a suspension of ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate polymorph I in acetone to 45° C. to 50° C. for approximately 4 hours;
(b) optionally (i) inoculating the mixture of step (a) with ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate (polymorph II) crystals, or (ii) inoculating the mixture of step (a) with ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate (polymorph II) crystals and additionally adding a small amount of ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate base;
(c) cooling the mixture of the previous step to approximately 15° C. to precipitate crystals of ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate (polymorph II);
(d) suction filtering the precipitated crystals of ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate (polymorph II); and
(e) drying the precipitated crystals of ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate (polymorph II) thus obtained in vacuo for at least 4 hours at a maximum of 50° C.
13. A process for preparing a polymorph of ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate in crystalline form, the process comprising:
(a) ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate (polymorph I) is placed in acetone;
(b) optionally (i) inoculating the mixture of step (a) with a small amount of crystals of ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate (polymorph II), or (ii) inoculating the mixture of step (a) with crystals of ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate (polymorph II) and additionally a small amount of ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate base is added;
(c) heating the mixture of the previous step to 40° C. to 46° C. for at least one hour with stirring;
(d) cooling the mixture of step (c) to approximately 17° C. to 23° C. and stirring for a further 40 to 80 minutes at this temperature;
(e) separating the precipitated crystals of ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate (polymorph II); and
(f) drying the precipitated crystals of ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate (polymorph II) thus obtained in vacuo for at least 4 hours at a maximum of 50° C.
14. A process for preparing a polymorph of ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate hemihydrate in crystalline form, the process comprising:
(a) slowly adding a solution of one equivalent of methanesulfonic acid in ethyl acetate to a solution of ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate base in a mixture of 90% aqueous ethanol and ethyl acetate in a ratio by volume of approximately 2:5 at a temperature of approximately 35° C. to 40° C.;
(b) optionally adding further ethyl acetate for dilution as the product begins to crystallize out;
(c) stirring the mixture of the previous step for about another 30 minutes at approximately 35° C. to 40° C.;
(d) stirring the mixture of step (c) for a further 30 minutes at ambient room temperature;
(e) suction filtering the precipitate of ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate hemihydrate; and
(f) dried at approximately 40° C. in the circulating air drying cupboard.
15. The product of the process of claim 10 .
16. The product of the process of claim 11 .
17. The product of the process of claim 12 .
18. The product of the process of claim 14 .
19. The product of the process of claim 15.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/918,017 US20050234104A1 (en) | 2003-08-29 | 2004-08-13 | 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as medicament |
US12/022,655 US7932273B2 (en) | 2003-08-29 | 2008-01-30 | 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10339862A DE10339862A1 (en) | 2003-08-29 | 2003-08-29 | New crystalline forms of ethyl 3-(N-(2-(4-(hexyloxycarbonylamidino)phenylaminomethyl)-1-methyl-1H-benzimidazole-5-carbonyl)-N-(2-pyridyl)amino)propionate methanesulfonate used for post-operative prophylaxis of deep vein thrombosis |
DE10339862.7 | 2003-08-29 | ||
US50331603P | 2003-09-16 | 2003-09-16 | |
US10/918,017 US20050234104A1 (en) | 2003-08-29 | 2004-08-13 | 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as medicament |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/022,655 Continuation US7932273B2 (en) | 2003-08-29 | 2008-01-30 | 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050234104A1 true US20050234104A1 (en) | 2005-10-20 |
Family
ID=34202202
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/918,017 Abandoned US20050234104A1 (en) | 2003-08-29 | 2004-08-13 | 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as medicament |
US12/022,655 Active 2025-09-07 US7932273B2 (en) | 2003-08-29 | 2008-01-30 | 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/022,655 Active 2025-09-07 US7932273B2 (en) | 2003-08-29 | 2008-01-30 | 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament |
Country Status (36)
Country | Link |
---|---|
US (2) | US20050234104A1 (en) |
EP (2) | EP1660482B1 (en) |
JP (2) | JP5348842B2 (en) |
KR (1) | KR101331039B1 (en) |
CN (2) | CN1845917B (en) |
AR (2) | AR045520A1 (en) |
AT (2) | ATE529420T1 (en) |
AU (2) | AU2004274139B2 (en) |
BR (1) | BRPI0413849A (en) |
CA (2) | CA2749579C (en) |
CO (1) | CO5660265A2 (en) |
CY (2) | CY1109299T1 (en) |
DE (2) | DE10339862A1 (en) |
DK (2) | DK1660482T3 (en) |
EA (1) | EA009736B1 (en) |
EC (2) | ECSP066399A (en) |
ES (2) | ES2375896T3 (en) |
HK (2) | HK1157760A1 (en) |
HR (2) | HRP20090311T1 (en) |
IL (1) | IL173885A (en) |
ME (1) | ME00340B (en) |
MX (1) | MXPA06001959A (en) |
MY (2) | MY145696A (en) |
NO (2) | NO334115B1 (en) |
NZ (2) | NZ578586A (en) |
PE (1) | PE20050348A1 (en) |
PL (2) | PL1660482T3 (en) |
PT (2) | PT1660482E (en) |
RS (2) | RS53370B (en) |
SG (1) | SG145734A1 (en) |
SI (2) | SI1660482T1 (en) |
TW (2) | TWI418553B (en) |
UA (1) | UA85686C2 (en) |
UY (2) | UY28493A1 (en) |
WO (1) | WO2005028468A1 (en) |
ZA (1) | ZA200600518B (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030181488A1 (en) * | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
US20080027057A1 (en) * | 2002-10-10 | 2008-01-31 | Chris Rundfeldt | Use of dihydroimidazolones for the treatment of dogs |
US20100144796A1 (en) * | 2006-11-16 | 2010-06-10 | Boehringer Ingelheim Pharma Gmbh & Co.Kg | New polymorphs of ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino- methyl)-phenylamino]-methyl-1-methyl-1h-benzimidazole-5-carbonyl) -pyridin-2-yl-amino]-propionate |
US20110123635A1 (en) * | 2008-07-14 | 2011-05-26 | Boehringer Ingelheim International Gmbh | Method for manufacturing medicinal compounds containing dabigatran |
US20110129538A1 (en) * | 2008-03-28 | 2011-06-02 | Boehringer Ingelheim International Gmbh | Process for preparing orally administered dabigatran formulations |
US20110190352A1 (en) * | 2008-08-19 | 2011-08-04 | Boehringer Ingelheim International Gmbh | Use of dabigatranetexilate for treating patients with pulmonary hypertension |
WO2011110876A1 (en) | 2010-02-02 | 2011-09-15 | Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság | Novel salts for the manufacture of pharmaceutical compositions |
WO2012027543A1 (en) | 2010-08-25 | 2012-03-01 | Teva Pharmaceuticals Usa, Inc. | Solid state forms of dabigatran etexilate, dabigatran etexilate mesylate and processes for preparation thereof |
WO2012162492A1 (en) | 2011-05-24 | 2012-11-29 | Teva Pharmaceutical Industries Ltd. | Compressed core comprising organic acids for a pharmaceutical composition |
WO2014033693A1 (en) | 2012-08-31 | 2014-03-06 | Ranbaxy Laboratories Limited | Process for the preparation of crystalline form i of methanesulfonate salt of dabigatran etexilate |
US9006448B2 (en) | 2010-12-06 | 2015-04-14 | Msn Laboratories Private Limited | Process for the preparation of benzimidazole derivatives and its salts |
WO2015128875A2 (en) | 2014-02-26 | 2015-09-03 | Megafine Pharma (P) Ltd. | A process for preparation of dabigatran etexilate mesylate and intermediates thereof |
US9273030B2 (en) | 2012-04-02 | 2016-03-01 | Msn Laboratories Private Limited | Process for the preparation of benzimidazole derivatives and salts thereof |
US9820988B2 (en) | 2014-03-24 | 2017-11-21 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of epileptic disorders in feline animals |
US11013729B2 (en) | 2012-02-21 | 2021-05-25 | Towa Pharmaceutical Europe, S.L. Unipersonal | Oral pharmaceutical compositions of dabigatran etexilate |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10337697A1 (en) * | 2003-08-16 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tablet containing 3 - [(2 - {[4- (hexyloxycarbonylamino-iminomethyl) -phenyl-amino] -methyl} -1-methyl-1H-benzimidazole-5-carbonyl) -pyridin-2-yl-amino] - propionic acid ethyl ester or its salts |
DE102005020002A1 (en) * | 2005-04-27 | 2006-11-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New hexyloxycarbonylamino-imino-methyl-phenylamino-methyl-benzimidazole-pyridine-propionic acid-ethyl ester salts such as hydrochloride useful for the prophylaxis of vein thrombosis and stroke |
DE102005025728A1 (en) * | 2005-06-04 | 2006-12-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Polymorphs of 3 - [(2 - {[4- (hexyloxycarbonylamino-imino-methyl) -phenyl-amino] -methyl} -1-methyl-1H-benzimidazole-5-carbonyl) -pyridin-2-yl-amino] -propionic acid ethyl ester |
CN102209544A (en) | 2008-11-11 | 2011-10-05 | 贝林格尔.英格海姆国际有限公司 | Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy |
US20120142703A1 (en) | 2009-05-14 | 2012-06-07 | Boehringer Ingelheim International Gmbh | New combination therapy in treatment of oncological and fibrotic diseases |
US20130052262A1 (en) * | 2010-03-01 | 2013-02-28 | Sandra Brueck | Dabigatran etexilate-containing oral pharmaceutical composition |
CA2792273A1 (en) | 2010-03-08 | 2011-09-15 | Ratiopharm Gmbh | Dabigatran etexilate-containing pharmaceutical composition |
PT2588090T (en) | 2010-07-01 | 2017-06-26 | Krka Tovarna Zdravil D D Novo Mesto | Pharmaceutical oral dosage forms comprising dabigatran etexilate and its pharmaceutically acceptable salts |
EP2603503B1 (en) | 2010-09-27 | 2015-08-05 | ratiopharm GmbH | Dabigatran etexilate bismesylate salt, solid state forms and process for preparation thereof |
HUP1100244A2 (en) | 2011-05-11 | 2012-11-28 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Pharmaceutical intermediates and process for their production |
CA2860098A1 (en) | 2011-12-22 | 2013-06-27 | Boehringer Ingelheim International Gmbh | Immediate release multi unit pellet system |
US9212166B2 (en) | 2012-01-20 | 2015-12-15 | Cadila Healthcare Limited | Process for the preparation of dabigatran etexilate mesylate and polymorphs of intermediates thereof |
JP2015504903A (en) | 2012-01-24 | 2015-02-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | New dabigatran formulation for oral administration |
EP2631234A1 (en) | 2012-02-23 | 2013-08-28 | Esteve Química, S.A. | Solid forms of dabigatran etexilate mesylate and processes for their preparation |
WO2013144971A1 (en) | 2012-03-27 | 2013-10-03 | Cadila Healthcare Limited | New solid forms of dabigatran etexilate bisulfate and mesylate and processes to prepare them |
JP2015522596A (en) * | 2012-07-16 | 2015-08-06 | インテルキム、ソシエダッド アノニマ | Process for preparing an intermediate for the synthesis of dabigatran etexilate and crystal forms of the intermediate |
CN103664882A (en) * | 2012-09-20 | 2014-03-26 | 天津药物研究院 | Dabigatran etexilate in crystal modification form, and preparation method and use of dabigatran etexilate |
CN103864756B (en) * | 2012-12-11 | 2018-06-15 | 四川海思科制药有限公司 | Fourth disulfonic acid dabigatran etcxilate and its preparation method and application |
EP2835370A1 (en) | 2013-08-08 | 2015-02-11 | Medichem, S.A. | New crystals of dabigatran etexilate mesylate |
CN104418840A (en) * | 2013-09-05 | 2015-03-18 | 天津汉瑞药业有限公司 | Dabigatran etexilate mesylate anhydrous compound |
CN104892574A (en) * | 2014-03-04 | 2015-09-09 | 浙江海正药业股份有限公司 | Dabigatran etexilate mesylate crystal forms, preparation methods and uses thereof |
CN108947966A (en) * | 2014-04-04 | 2018-12-07 | 江苏天士力帝益药业有限公司 | Dabigatran etcxilate mesylate novel crystal forms and preparation method thereof |
CN105461686A (en) * | 2014-08-25 | 2016-04-06 | 江苏豪森药业股份有限公司 | Preparation method of high purity Pradaxa crystal form |
CN104825422B (en) * | 2014-09-29 | 2017-12-12 | 普济生物科技(台州)有限公司 | Pharmaceutical composition containing dabigatran etcxilate mesylate and preparation method thereof |
WO2016107605A1 (en) | 2014-12-31 | 2016-07-07 | 昆明积大制药股份有限公司 | Pharmaceutical composition and preparation method therefor |
CN104725360A (en) * | 2015-04-09 | 2015-06-24 | 重庆东得医药科技有限公司 | Preparing method of dabigatran etexilate mesylate crystal form I |
WO2017111637A1 (en) | 2015-12-23 | 2017-06-29 | Zaklady Farmaceutyczne Polpharma Sa | Pharmaceutical composition comprising dabigatran or a pharmaceutically acceptable salt thereof |
US10449195B2 (en) | 2016-03-29 | 2019-10-22 | Shenzhen Pharmacin Co., Ltd. | Pharmaceutical formulation of palbociclib and a preparation method thereof |
CN107778291A (en) * | 2016-08-31 | 2018-03-09 | 亚宝药业集团股份有限公司 | A kind of preparation method of dabigatran etexilate methanesulfonate crystal formation II |
KR20210086682A (en) | 2018-10-29 | 2021-07-08 | 화하이 유에스 인코퍼레이티드 | Novel dipeptide compounds and uses thereof |
JP2020193184A (en) * | 2019-05-30 | 2020-12-03 | ダイト株式会社 | Method for preparing form i of dabigatran etexilate methanesulphonate |
EP3771465A1 (en) | 2019-08-01 | 2021-02-03 | Zaklady Farmaceutyczne Polpharma SA | Pharmaceutical composition comprising dabigatran etexilate |
CN114306245A (en) | 2020-09-29 | 2022-04-12 | 深圳市药欣生物科技有限公司 | Pharmaceutical composition of amorphous solid dispersion and preparation method thereof |
CN114380793B (en) * | 2020-10-20 | 2024-02-23 | 北京澳合药物研究院有限公司 | Preparation method and application of dabigatran etexilate mesylate crystal form I |
US11446286B1 (en) * | 2022-02-28 | 2022-09-20 | King Faisal University | Treatment of fungal infections using dabigatran etexilate |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030181488A1 (en) * | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
US20050038077A1 (en) * | 2003-08-16 | 2005-02-17 | Boehringer Ingelheim International Gmbh | Tablet containing 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H- benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethylester or the salts thereof |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6087380A (en) * | 1949-11-24 | 2000-07-11 | Boehringer Ingelheim Pharma Kg | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
US4427468A (en) * | 1976-01-16 | 1984-01-24 | Her Majesty The Queen In Right Of Canada | Curable propellant binding systems with bonding agent combination |
DE3000979A1 (en) * | 1980-01-12 | 1981-07-23 | Dr. Karl Thomae Gmbh, 7950 Biberach | NEW DIPYRIDAMOL RETARD FORMS AND METHOD FOR THEIR PRODUCTION |
DE3124090A1 (en) * | 1981-06-19 | 1983-01-05 | Dr. Karl Thomae Gmbh, 7950 Biberach | NEW ORAL DIPYRIDAMOL FORMS |
DE3126703A1 (en) * | 1981-07-07 | 1983-01-27 | Dr. Karl Thomae Gmbh, 7950 Biberach | BROMHEXIN RETARD FORM AND METHOD FOR THEIR PRODUCTION |
JPS58134033A (en) | 1982-02-02 | 1983-08-10 | Fujisawa Pharmaceut Co Ltd | Drug composition |
US4675405A (en) * | 1984-09-21 | 1987-06-23 | American Home Products Corporation | Quinoline compounds as antiallergic and antithrombotic agents |
DE4129603A1 (en) * | 1991-09-06 | 1993-03-11 | Thomae Gmbh Dr K | CONDENSED 5-LOW HETEROCYCLES, METHOD FOR THE PRODUCTION THEREOF, AND MEDICAMENTS CONTAINING THESE COMPOUNDS |
US5416099A (en) * | 1991-10-29 | 1995-05-16 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
ZA928276B (en) | 1991-10-31 | 1993-05-06 | Daiichi Seiyaku Co | Aromatic amidine derivates and salts thereof. |
NZ253999A (en) * | 1992-08-05 | 1996-07-26 | Faulding F H & Co Ltd | Pelletised substained release medicament |
JPH06340619A (en) | 1993-05-03 | 1994-12-13 | Bristol Myers Squibb Co | Guanidyl- or amidinyl-substituted methylamino heterocyclic thrombin inhibitor |
CA2134192A1 (en) | 1993-11-12 | 1995-05-13 | Michael L. Denney | 5, 6-bicyclic glycoprotein iib/iiia antagonists |
PE121699A1 (en) | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | BICYCLE HETERO CYCLES DISSTITUTED AS INHIBITORS OF THROMBIN |
US6414008B1 (en) * | 1997-04-29 | 2002-07-02 | Boehringer Ingelheim Pharma Kg | Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions |
DE19752843C2 (en) | 1997-11-28 | 2003-01-09 | Byk Gulden Lomberg Chem Fab | Pharmaceutical preparation in tablet or pellet form for pantoprazole and omeprazole |
DE10133786A1 (en) | 2001-07-16 | 2003-02-06 | Boehringer Ingelheim Pharma | Use of thrombin inhibitors for the treatment of arthritis |
US6627646B2 (en) * | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
DE10245624A1 (en) * | 2002-09-30 | 2004-04-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Oral pharmaceutical composition comprises the thrombin inhibitor ethyl 3-(2-(4-(hexyloxycarbonylamidino)phenylaminomethyl)-1-methyl-1H-benzimidazole-5-carbonyl)-2-pyridylamino)propionate and an organic acid |
DE10209982A1 (en) * | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma | Dosage form to be administered orally for poorly soluble basic active ingredients |
SG146435A1 (en) * | 2002-03-07 | 2008-10-30 | Boehringer Ingelheim Pharma | Form of presentation for 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl- amino] propionic acid ethyl ester to be administered orally |
DE10235639A1 (en) * | 2002-08-02 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New prodrugs of benzimidazole-5-carboxamide derivative thrombin inhibitor, useful for treating or preventing thrombotic diseases, are well tolerated on subcutaneous injection |
BRPI0409796A (en) * | 2003-04-24 | 2006-05-30 | Boehringer Ingelheim Int | use of dipyridamole or mopidamole for treatment and prevention of thromboembolic disorders and disorders caused by excessive thrombin formation and / or elevated expression of thrombin receptors |
US20050107438A1 (en) * | 2003-09-03 | 2005-05-19 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising 3-[(2-{[4-(Hexyloxycarbonylaminoiminomethyl) phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester or a salt therefore |
EP1609784A1 (en) * | 2004-06-25 | 2005-12-28 | Boehringer Ingelheim Pharma GmbH & Co.KG | Process for the preparation of 4-(benzimidazolylmethylamino)-benzamidines |
US20060222640A1 (en) * | 2005-03-29 | 2006-10-05 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions for treatment of thrombosis |
DE102005020002A1 (en) * | 2005-04-27 | 2006-11-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New hexyloxycarbonylamino-imino-methyl-phenylamino-methyl-benzimidazole-pyridine-propionic acid-ethyl ester salts such as hydrochloride useful for the prophylaxis of vein thrombosis and stroke |
DE102005025728A1 (en) * | 2005-06-04 | 2006-12-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Polymorphs of 3 - [(2 - {[4- (hexyloxycarbonylamino-imino-methyl) -phenyl-amino] -methyl} -1-methyl-1H-benzimidazole-5-carbonyl) -pyridin-2-yl-amino] -propionic acid ethyl ester |
DE102005061624A1 (en) * | 2005-12-21 | 2007-06-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Improved process for the preparation of salts of 4- (benzimidazolylmethylamino) -benzamidines |
DE102005061623A1 (en) * | 2005-12-21 | 2007-06-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Improved process for the preparation of 4- (benzimidazolylmethylamino) -benzamidines and their salts |
-
2003
- 2003-08-29 DE DE10339862A patent/DE10339862A1/en not_active Withdrawn
-
2004
- 2004-08-13 US US10/918,017 patent/US20050234104A1/en not_active Abandoned
- 2004-08-24 AT AT09153155T patent/ATE529420T1/en active
- 2004-08-24 CA CA2749579A patent/CA2749579C/en active Active
- 2004-08-24 UA UAA200603253A patent/UA85686C2/en unknown
- 2004-08-24 AT AT04764411T patent/ATE430145T1/en active
- 2004-08-24 WO PCT/EP2004/009432 patent/WO2005028468A1/en active Application Filing
- 2004-08-24 SI SI200431177T patent/SI1660482T1/en unknown
- 2004-08-24 EP EP04764411A patent/EP1660482B1/en active Active
- 2004-08-24 DE DE502004009431T patent/DE502004009431D1/en active Active
- 2004-08-24 PL PL04764411T patent/PL1660482T3/en unknown
- 2004-08-24 RS RS20060136A patent/RS53370B/en unknown
- 2004-08-24 NZ NZ578586A patent/NZ578586A/en unknown
- 2004-08-24 AU AU2004274139A patent/AU2004274139B2/en active Active
- 2004-08-24 JP JP2006524316A patent/JP5348842B2/en active Active
- 2004-08-24 SI SI200431794T patent/SI2060569T1/en unknown
- 2004-08-24 CN CN2004800249521A patent/CN1845917B/en active Active
- 2004-08-24 ME MEP-2008-506A patent/ME00340B/en unknown
- 2004-08-24 PT PT04764411T patent/PT1660482E/en unknown
- 2004-08-24 ES ES09153155T patent/ES2375896T3/en active Active
- 2004-08-24 CN CN2011100536316A patent/CN102167695B/en active Active
- 2004-08-24 EP EP09153155A patent/EP2060569B1/en not_active Revoked
- 2004-08-24 BR BRPI0413849-0A patent/BRPI0413849A/en not_active Application Discontinuation
- 2004-08-24 NZ NZ545984A patent/NZ545984A/en unknown
- 2004-08-24 PL PL09153155T patent/PL2060569T3/en unknown
- 2004-08-24 RS YUP-2006/0136A patent/RS20060136A/en unknown
- 2004-08-24 ES ES04764411T patent/ES2326654T3/en active Active
- 2004-08-24 DK DK04764411T patent/DK1660482T3/en active
- 2004-08-24 PT PT09153155T patent/PT2060569E/en unknown
- 2004-08-24 EA EA200600381A patent/EA009736B1/en not_active IP Right Cessation
- 2004-08-24 DK DK09153155.8T patent/DK2060569T3/en active
- 2004-08-24 CA CA2537054A patent/CA2537054C/en active Active
- 2004-08-24 SG SG200805933-9A patent/SG145734A1/en unknown
- 2004-08-24 MX MXPA06001959A patent/MXPA06001959A/en active IP Right Grant
- 2004-08-24 KR KR1020067003994A patent/KR101331039B1/en active IP Right Grant
- 2004-08-26 MY MYPI20093734A patent/MY145696A/en unknown
- 2004-08-26 MY MYPI20043499A patent/MY145632A/en unknown
- 2004-08-27 AR ARP040103089A patent/AR045520A1/en active Pending
- 2004-08-27 UY UY28493A patent/UY28493A1/en not_active Application Discontinuation
- 2004-08-27 PE PE2004000824A patent/PE20050348A1/en not_active Application Discontinuation
- 2004-08-27 TW TW100125555A patent/TWI418553B/en not_active IP Right Cessation
- 2004-08-27 TW TW093125929A patent/TWI375674B/en not_active IP Right Cessation
-
2006
- 2006-01-18 ZA ZA2006/00518A patent/ZA200600518B/en unknown
- 2006-02-23 IL IL173885A patent/IL173885A/en active IP Right Grant
- 2006-02-28 CO CO06019918A patent/CO5660265A2/en not_active Application Discontinuation
- 2006-03-01 EC EC2006006399A patent/ECSP066399A/en unknown
- 2006-03-28 NO NO20061420A patent/NO334115B1/en not_active IP Right Cessation
-
2007
- 2007-03-15 HK HK11112042.0A patent/HK1157760A1/en not_active IP Right Cessation
- 2007-03-15 HK HK07102805.4A patent/HK1096682A1/xx not_active IP Right Cessation
-
2008
- 2008-01-30 US US12/022,655 patent/US7932273B2/en active Active
-
2009
- 2009-05-27 HR HR20090311T patent/HRP20090311T1/en unknown
- 2009-07-23 CY CY20091100788T patent/CY1109299T1/en unknown
- 2009-08-28 AR ARP090103316A patent/AR073225A2/en unknown
- 2009-12-18 UY UY0001032342A patent/UY32342A/en not_active Application Discontinuation
-
2010
- 2010-04-13 AU AU2010201457A patent/AU2010201457B2/en active Active
-
2011
- 2011-05-09 JP JP2011104428A patent/JP5566332B2/en active Active
- 2011-11-21 EC EC2011006399A patent/ECSP11006399A/en unknown
-
2012
- 2012-01-10 HR HR20120028T patent/HRP20120028T1/en unknown
- 2012-01-11 CY CY20121100024T patent/CY1112222T1/en unknown
-
2013
- 2013-06-05 NO NO20130778A patent/NO20130778L/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030181488A1 (en) * | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
US20050038077A1 (en) * | 2003-08-16 | 2005-02-17 | Boehringer Ingelheim International Gmbh | Tablet containing 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H- benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethylester or the salts thereof |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060183779A1 (en) * | 2002-03-07 | 2006-08-17 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
US20030181488A1 (en) * | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
US9925174B2 (en) | 2002-03-07 | 2018-03-27 | Boehringer Ingelheim International Gmbh | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof |
US8859540B2 (en) | 2002-10-10 | 2014-10-14 | Boehringer Ingelheim Vetmedica Gmbh | Use of dihydroimidazolones for the treatment of dogs |
US20080027057A1 (en) * | 2002-10-10 | 2008-01-31 | Chris Rundfeldt | Use of dihydroimidazolones for the treatment of dogs |
US9469611B2 (en) | 2002-10-10 | 2016-10-18 | Boehringer Ingelheim Vetmedica Gmbh | Use of dihydroimidazolones for the treatment of dogs |
US8962617B2 (en) | 2002-10-10 | 2015-02-24 | Boehringer Ingelheim Vetmedica Gmbh | Use of dihydroimidazolones for the treatment of dogs |
US20100144796A1 (en) * | 2006-11-16 | 2010-06-10 | Boehringer Ingelheim Pharma Gmbh & Co.Kg | New polymorphs of ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino- methyl)-phenylamino]-methyl-1-methyl-1h-benzimidazole-5-carbonyl) -pyridin-2-yl-amino]-propionate |
US20110129538A1 (en) * | 2008-03-28 | 2011-06-02 | Boehringer Ingelheim International Gmbh | Process for preparing orally administered dabigatran formulations |
US20110123635A1 (en) * | 2008-07-14 | 2011-05-26 | Boehringer Ingelheim International Gmbh | Method for manufacturing medicinal compounds containing dabigatran |
US9089488B2 (en) * | 2008-07-14 | 2015-07-28 | Boehringer Ingelheim International Gmbh | Method for manufacturing medicinal compounds containing dabigatran |
US20130251811A1 (en) * | 2008-07-14 | 2013-09-26 | Boehringer Ingelheim International Gmbh | Method for manufacturing medicinal compounds containing dabigatran |
US20110190352A1 (en) * | 2008-08-19 | 2011-08-04 | Boehringer Ingelheim International Gmbh | Use of dabigatranetexilate for treating patients with pulmonary hypertension |
WO2011110876A1 (en) | 2010-02-02 | 2011-09-15 | Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság | Novel salts for the manufacture of pharmaceutical compositions |
WO2012027543A1 (en) | 2010-08-25 | 2012-03-01 | Teva Pharmaceuticals Usa, Inc. | Solid state forms of dabigatran etexilate, dabigatran etexilate mesylate and processes for preparation thereof |
US9006448B2 (en) | 2010-12-06 | 2015-04-14 | Msn Laboratories Private Limited | Process for the preparation of benzimidazole derivatives and its salts |
WO2012162492A1 (en) | 2011-05-24 | 2012-11-29 | Teva Pharmaceutical Industries Ltd. | Compressed core comprising organic acids for a pharmaceutical composition |
US11752142B2 (en) | 2012-02-21 | 2023-09-12 | Breckenridge Pharmaceutical, Inc. | Oral pharmaceutical compositions of dabigatran etexilate |
US11013729B2 (en) | 2012-02-21 | 2021-05-25 | Towa Pharmaceutical Europe, S.L. Unipersonal | Oral pharmaceutical compositions of dabigatran etexilate |
US9273030B2 (en) | 2012-04-02 | 2016-03-01 | Msn Laboratories Private Limited | Process for the preparation of benzimidazole derivatives and salts thereof |
WO2014033693A1 (en) | 2012-08-31 | 2014-03-06 | Ranbaxy Laboratories Limited | Process for the preparation of crystalline form i of methanesulfonate salt of dabigatran etexilate |
US9150542B2 (en) | 2012-08-31 | 2015-10-06 | Ranbaxy Laboratories Limited | Process for the preparation of crystalline form I of methanesulfonate salt of dabigatran etexilate |
WO2015128875A3 (en) * | 2014-02-26 | 2015-11-12 | Megafine Pharma (P) Ltd. | A process for preparation of dabigatran etexilate mesylate and intermediates thereof |
WO2015128875A2 (en) | 2014-02-26 | 2015-09-03 | Megafine Pharma (P) Ltd. | A process for preparation of dabigatran etexilate mesylate and intermediates thereof |
US9820988B2 (en) | 2014-03-24 | 2017-11-21 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of epileptic disorders in feline animals |
US10420774B2 (en) | 2014-03-24 | 2019-09-24 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of epileptic disorders in feline animals |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7932273B2 (en) | 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament | |
KR101019451B1 (en) | Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form ? | |
US7300938B2 (en) | Polymorphs of imatinib mesylate | |
US8232293B2 (en) | Crystalline forms of a potent HCV inhibitor | |
US20100144796A1 (en) | New polymorphs of ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino- methyl)-phenylamino]-methyl-1-methyl-1h-benzimidazole-5-carbonyl) -pyridin-2-yl-amino]-propionate | |
US20060276513A1 (en) | Polymorphs of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H- benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester | |
US20060247278A1 (en) | Physiologically acceptable salts of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester | |
US20040010151A1 (en) | Lansoprazole polymorphs and processes for preparation thereof | |
US7977348B2 (en) | Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α | |
US7135485B2 (en) | Pioglitazone hydrochloride | |
JP2019509320A (en) | Novel acid addition salts of 1- (5- (2,4-difluorophenyl) -1-((3-fluorophenyl) sulfonyl) -4-methoxy-1H-pyrrol-3-yl) -N-methylmethanamine | |
US20060135565A1 (en) | Crystalline form of rabeprazole sodium | |
US8067421B2 (en) | Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α | |
US7678816B2 (en) | Method of stabilizing lansoprazole | |
US9034904B2 (en) | Forms of dexlansoprazole and processes for the preparation thereof | |
KR20130041381A (en) | 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethylester-methanesulfonate and pharmaceutical composition comprising the same | |
JP2007514734A (en) | 2- {4-'3- (4-Chloro-2-fluorophenyl) -4-pyrimidin-4-yl-1H-pyrazol-5-yl! Crystalline form of piperidin-1-yl} -2-oxoethanol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BOEHRINGER INGELHEIM INTERNATIONAL GMBH, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SCHMID, ROLF;SIEGER, PETER;SOBOTTA, RAINER;REEL/FRAME:015545/0008;SIGNING DATES FROM 20041202 TO 20041209 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |